RNA's Biggest Problem Has a $54M Bet Behind It
Almost every RNA drug on the market goes to the liver. Vivatides Therapeutics just raised $54 million to deliver RNA everywhere else, tackling one of biotech's hardest unsolved problems.
Almost every RNA drug on the market does the same thing: it goes to the liver. That's not a coincidence. It's a limitation.
The liver is basically RNA medicine's comfort zone. Thanks to a delivery trick called GalNAc conjugation (a sugar molecule that acts like a GPS signal for liver cells), companies like Alnylam have built blockbuster drugs that silence disease-causing genes in liver tissue. But the rest of the body? Kidneys, lungs, muscles, brain, heart? That's still largely off-limits.
A startup called Vivatides Therapeutics just raised $54 million in a Series A to try to change that. The round, which closed on April 10, was co-led by Qiming Venture Partners and an unnamed industry fund, with participation from Highlight Capital, TF Capital, and existing backer Apricot Capital. For a company founded just last year, that's a serious vote of confidence.
Why RNA Can't Leave the Liver
Think of it like a postal system that only delivers to one zip code. The packaging technology that protects RNA drugs in the bloodstream (lipid nanoparticles, or LNPs) has a natural tendency to accumulate in the liver. That's because LNPs attract a protein in the blood called ApoE, which essentially flags them for liver cell pickup.
This "liver tropism" isn't a bug that snuck into the system. It's baked into the physics and biology of how these particles behave. Even when scientists try to redirect them elsewhere, the liver acts like a magnet, pulling most of the payload away from the intended target.
Beyond the liver problem, RNA molecules themselves are difficult passengers. They carry a strong negative charge, making it hard for them to cross cell membranes. They're also fragile in the bloodstream, where enzymes chew them up quickly. And even when they reach the right tissue, they often get trapped inside cellular compartments called endosomes, never making it to where they actually need to work.
So delivering RNA to the lungs or brain isn't just "hard mode." It's a fundamentally different engineering challenge.
What Vivatides Is Building
Vivatides, headquartered in Suzhou, China, with a presence in Boston, is developing a proprietary platform for delivering two types of RNA therapeutics outside the liver: (small interfering RNA, which silences specific genes) and (antisense oligonucleotides, which can modify or block gene activity).
More from this issue
View full issue →
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
